Could a common Anti-Inflammatory pill boost biologic therapy for ulcerative colitis?

NCT ID NCT05205603

Completed Disease control Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether adding mesalazine (a standard anti-inflammatory drug) to biologic treatments like infliximab or vedolizumab helps people with moderate to severe ulcerative colitis achieve endoscopic remission (healing of the gut lining). The trial enrolled 438 adults and followed them for 12 months. The goal is to see if the combination works better than biologics alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mesalazine combined with a biologic (infliximab or vedolizumab)
What this could lead to: If it works, this could show that adding mesalazine to standard biologic therapy helps more people achieve endoscopic remission, potentially improving long-term disease control.
What could go wrong: This is a Phase 4 study, so the drugs are already approved, but the benefit of adding mesalazine is unclear. The trial is completed but results are not yet reported, so we don't know if the combination is truly better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOLOGICS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOLOGICS EFFICACY, SELF MESALAZINE ULCERATIVE COLITIS

Contacts and locations

Locations

First Affiliated Hospital of Shantou University Medical College

Shantou, Guangdong, China
First People's Hospital of Foshan

Guangzhou, Guangdong, China
General Hospital of Tianjin Medical University

Tianjin, Tianjin Municipality, China
Guangzhou Panyu Central Hospital

Guangzhou, Guangdong, China
Nanhai Hospital, Southern Medical University

Guangzhou, Guangdong, China
People's Hospital of Chongqing

Chongqing, Chongqing Municipality, China
Shengjing Hospital

Shenyang, Liaoning, China
Shunde Hospital of Southern Medical University

Guangzhou, Guangdong, China
The Second Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, China
Zhejiang University

Hanzhou, Zhejiang, China
the Sixth Affiliated Hospital of Sun Yat-Sen University

Guangzhou, Guangdong, 501655, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.